Pancreatic Cancer Research

ResearcherUniversity of OxfordActive in the last 2 years

Eric E. O’Neill

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0060-6278; OpenAlex author ID A5048742778. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 14

  1. Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control. Co-author DOI 10.1136/gutjnl-2024-333492↗
  2. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/ra… Co-author DOI 10.1016/j.ejca.2024.114236↗
  3. Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized therapy. Last author DOI 10.1126/sciadv.adm9071↗
  4. Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity. Last author DOI 10.7554/elife.92672↗
  5. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer. Co-author DOI 10.1038/s41418-023-01168-3↗
  6. Chemical-induced gene expression ranking and its application to pancreatic cancer drug repurposing. Co-author DOI 10.1016/j.patter.2022.100441↗
  7. Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1038/s41416-020-01120-z↗
  8. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. Last author DOI 10.1053/j.gastro.2021.04.044↗
  9. RAS in pancreatic cancer. Last author DOI 10.1042/bst20170521↗
  10. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for lo… Co-author DOI 10.1186/s12885-019-5307-z↗
  11. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-2833↗
  12. 89Zr-anti-γH2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-0664↗
  13. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.03.021↗
  14. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.6770↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Somnath Mukherjee · 9 shared papers, 2016–2024 · strength 1.03
  2. Frances W. Willenbrock · 4 shared papers, 2021–2025 · strength 0.65
  3. Simei Go · 3 shared papers, 2024–2025 · strength 0.62
  4. Tim Maughan · 5 shared papers, 2016–2024 · strength 0.50
  5. Keaton Ian Jones · 3 shared papers, 2017–2025 · strength 0.46
  6. Simone Lanfredini · 3 shared papers, 2019–2024 · strength 0.44
  7. Daniel Llwyd Hughes · 3 shared papers, 2021–2024 · strength 0.43
  8. Jennifer P. Morton · 2 shared papers, 2024–2025 · strength 0.40
  9. Chris N Hurt · 3 shared papers, 2019–2024 · strength 0.35
  10. Michael Eyres · 2 shared papers, 2021–2024 · strength 0.31
  11. M. Hawkins · 3 shared papers, 2016–2024 · strength 0.28
  12. Christopher Mark Jones · 2 shared papers, 2021–2024 · strength 0.27
  13. Ganesh Radhakrishna · 2 shared papers, 2019–2024 · strength 0.24
  14. Pippa G. Corrie · 2 shared papers, 2019–2024 · strength 0.24
  15. Shannon Nicole Russell · 1 shared paper, 2025 · strength 0.22
  16. Mathias Tesson · 1 shared paper, 2025 · strength 0.22
  17. Alex Nicolas Gordon-Weeks · 1 shared paper, 2025 · strength 0.22
  18. Zenobia D’Costa · 3 shared papers, 2016–2021 · strength 0.21
  19. Rachael J. M. Bashford-Rogers · 1 shared paper, 2024 · strength 0.18
  20. Shivan Sivakumar · 1 shared paper, 2024 · strength 0.18
  21. Thai-Hoang Pham · 1 shared paper, 2022 · strength 0.17
  22. Ping Zhang · 1 shared paper, 2022 · strength 0.17
  23. Paul Miller · 1 shared paper, 2023 · strength 0.17
  24. Xin Lü · 1 shared paper, 2023 · strength 0.17
  25. Emmanouil Fokas · 3 shared papers, 2016–2017 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.